Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621696 · ClinicalTrials.gov registry record · Phase 2
Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"
A Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT03621696: Active Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma, sponsored by Washington University School of Medicine.
NCT03621696 is a Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03621696, a Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.
Primary Outcome
* Weight in kilograms will be collected weekly during radiation * The percent weight loss from the baseline is calculated at any post-baseline
Conditions Studied
Interventions
- DRUG Cisplatin
- PROCEDURE Surgery
- RADIATION Intensity modulated radiation therapy
- RADIATION Intensity modulated proton therapy
- OTHER FACT-H&N
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2026-03-10 |
| Phase | Phase 2 |
What the registry record for NCT03621696 still lists
NCT03621696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with HPV Related Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT03621696 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03621696 about?
NCT03621696 is a clinical study titled "Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"". The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.
What is the current status of trial NCT03621696?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-10-23. Estimated completion is 2026-03-10.
What conditions does trial NCT03621696 study?
This clinical trial studies the following conditions: HPV Related Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03621696?
The interventions under investigation include: Cisplatin (DRUG), Surgery (PROCEDURE), Intensity modulated radiation therapy (RADIATION), Intensity modulated proton therapy (RADIATION), FACT-H&N (OTHER).
Who is sponsoring clinical trial NCT03621696?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03621696 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03621696's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI